Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-24T19:29:45.806Z Has data issue: false hasContentIssue false
  • English
  • Français

Serologic Testing for Protection against Hepatitis B Virus Infection among Students at a Health Sciences University in the United States

Published online by Cambridge University Press:  02 January 2015

Philip R. Spradling ,
Roxanne E. Williams ,
Jian Xing ,
Kenneth Soyemi  and
Joseph Towers
Philip R. Spradling*
Affiliation:
Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia
Roxanne E. Williams
Affiliation:
Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia
Jian Xing
Affiliation:
Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia
Kenneth Soyemi
Affiliation:
Illinois Department of Public Health, Chicago, Illinois
Joseph Towers
Affiliation:
Midwestern University, Downers Grove, Illinois
*
Division of Viral Hepatitis, National Center for HIV, Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Mailstop G37, 1600 Clifton Road NE, Atlanta, GA 30333 ([email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective.

To evaluate hepatitis B vaccination coverage and documentation of vaccine-induced immunity.

Design.

Retrospective cohort analysis.

Setting.

Graduate school in the United States with programs in osteopathic medicine, dentistry, and allied health.

Methods.

Data collected included demographics, dates of hepatitis B vaccine doses, and postvaccination concentrations of antibody to hepatitis B surface antigen (anti-HBs), with dates. The proportions of students with anti-HBs of 10 IU/L or more by demographics, age at vaccination, interval since completion of the primary series, and response to additional vaccine doses were compared.

Results.

Of 3,452 students who matriculated during 2004–2009, 2,643 had complete data; 2,481 (93.9%) received 3 primary doses. Most were women (64.6%), US-born (85.6%), and white (63.2%); median age at receipt of the primary series was 14.5 years (interquartile range, 11.6–20.2 years) and at postvaccination testing was 23.2 years (interquartile range, 22.1–24.8 years). Of those who received 3 primary doses, 2,306 (92.9%) had an anti-HBs postvaccination concentration of 10 IU/L or more. Younger age at vaccination and longer time interval from vaccination to anti-HBs testing were associated with a postvaccination concentration of less than 10 IU/L (P < .001 and P = .0185, respectively, Cochran-Armitage test for trend). Almost all students (98.2%) who initially had less than 10 IU/L of anti-HBs, but then received at least 1 additional dose, had a follow-up anti-HBs concentration of 10 IU/L or more.

Conclusions.

Almost all students had serologic evidence of protection against hepatitis B virus infection; most were vaccinated as adolescents and were tested more than 10 years after vaccination. Among students with anti-HBs concentrations of less than 10 IU/L, nearly all had 10 IU/L or more after at least 1 additional vaccine dose.

Type
Original Articles
Information
Infection Control & Hospital Epidemiology , Volume 33 , Issue 7 , July 2012 , pp. 732 - 736
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. CDC. Recommendation of the immunization practices advisory committee (ACIP) inactivated hepatitis B virus vaccine. MMWR 1982;31:317–322, 327-328.Google Scholar
2. CDC. Immunization of health-care personnel: recommendations of the advisory committee on immunization practices (ACIP). MMWR 2011;60(RR07):1–45. Available at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6007al.htm.Google Scholar
3. Leuridan, E, Van Damme, P. Hepatitis B and the need for a booster dose. Clin Infect Dis 2011;53:68–75.Google Scholar
4. CDC. Achievements in public health: hepatitis B vaccination—United States, 1982-2002. MMWR 2002;51:549–552, 563.Google Scholar
5. Lindley, MC, Lörick, SA, Spinner, JR, et al. Student vaccination requirements of US health professional schools: a survey. Ann Intern Med 2011;154:391–400.CrossRefGoogle ScholarPubMed
6. CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the advisory committee on immunization practices (ACIP), part II: immunization of adults. MMWR 2006; 55(RR16):1–33.Google Scholar